Tumour necrosis factor inhibitor-induced myositis in a patient with ulcerative colitis

References

• Weaver AL. Efficacy and safety of the anti-TNF biologic agents. Mod Rheumatol. 2004;14(2):101–112.
   Google Scholar
• Nam J, Emery P. Aspects of TNF inhibitor therapy in rheumatoid arthritis. Mod Rheumatol. 2010;20(4):325–330.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242–251.
   PubMed Web of Science ®Google Scholar
• Zengin O, Onder ME, Alkan S, et al. Three cases of anti-TNF induced myositis and literature review. Rev Bras Reumatol Engl Ed. 2017;57(6):590–595.
   Google Scholar
• Brunasso AM, Aberer W, Massone C. New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review. ScientificWorldJournal. 2014;2014:179180
   PubMedGoogle Scholar
• Musiał J, Undas A, Celińska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford). 2003;42(12):1566–1568.
   PubMed Web of Science ®Google Scholar
• Flendrie M, Creemers MC, Welsing PM, et al. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis. 2003;62(Suppl 2):ii30–ii33.
   Google Scholar
• Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7(3):R666–R676.
   PubMed Web of Science ®Google Scholar
• Urata Y, Wakai Y, Kowatari K, et al. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Mod Rheumatol. 2006;16(6):410–411.
   PubMedGoogle Scholar
• Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum. 2006;55(6):982–984.
   PubMed Web of Science ®Google Scholar
• Liozon E, Ouattara B, Loustaud-Ratti V, et al. Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma. Scand J Rheumatol. 2007;36(6):484–486.
   PubMed Web of Science ®Google Scholar
• Klein R, Rosenbach M, Kim EJ, et al. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010;146(7):780–784.
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Yukawa N, Ohmura K, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol. 2010;29(5):563–566.
   PubMed Web of Science ®Google Scholar
• Ishiguro T, Takayanagi N, Miyahara Y, et al. Antisynthetase (anti PL-7 antibody) syndrome presenting as a skin rash and exacerbation of interstitial pneumonia during treatment for rheumatoid arthritis. Nihon Kokyuki Gakkai Zasshi. 2010;48(3):240–246.
   Google Scholar
• Ishikawa Y, Yukawa N, Kawabata D, et al. A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept. Clin Rheumatol. 2011;30(3):429–432.
   Web of Science ®Google Scholar
• Brunasso AM, Scocco GL, Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol. 2010;37(7):1549–1550.
   PubMed Web of Science ®Google Scholar
• Kiltz U, Fendler C, Braun J. Neuromuscular involvement in rheumatic patients treated with anti-tumor necrosis factor therapy–three examples. J Rheumatol. 2008;35(10):2074–2076.
   PubMed Web of Science ®Google Scholar
• Liu SW, Velez NF, Lam C, et al. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis. JAMA Dermatol. 2013;149(10):1204–1208.
   PubMed Web of Science ®Google Scholar
• Riolo G, Towheed TE. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J Rheumatol. 2012;39(1):192–194.
   PubMed Web of Science ®Google Scholar
• Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(12):2271–2282.
   PubMed Web of Science ®Google Scholar
• Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14(5):337–345.
   PubMedGoogle Scholar
• Almoallim H, Al-Ghamdi Y, Almaghrabi H, et al. Anti-Tumor necrosis factor-α induced systemic lupus erythematosus. Open Rheumatol J. 2012;6:315–319.
   PubMedGoogle Scholar
• Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009;48(7):716–720.
   PubMed Web of Science ®Google Scholar
• Bergua C, Chiavelli H, Allenbach Y, et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis. 2019;78(1):131–139.
   PubMed Web of Science ®Google Scholar
• Vaglio A, Grayson PC, Fenaroli P, et al. Drug-induced lupus: traditional and new concepts. Autoimmun Rev. 2018;17(9):912–918.
   PubMed Web of Science ®Google Scholar
• Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis. 2018;5(2):109–129.
   PubMedGoogle Scholar